On April 29, 2026, in Hanoi, Nam Ha Pharmaceutical Joint Stock Company successfully held the 2026 Annual General Meeting of Shareholders with the full attendance of the Board of Directors, the Board of Management, and the Company’s shareholders.

The Meeting took place in a serious, transparent, and highly consensual atmosphere, demonstrating strong alignment in the Company’s development orientation in the new phase.

The 2026 Annual General Meeting of Shareholders of Nam Ha Pharma Was Successfully Held

2025 Business Performance: Maintaining Stability, Enhancing Efficiency 

At the Meeting, key reports on the 2025 business performance, the governance activities of the Board of Directors, and the development plan for 2026 were presented, discussed, and approved.

In 2025, amid significant fluctuations in the pharmaceutical market driven by the global economy, input cost pressures, and increasingly stringent quality management standards, Nam Ha Pharma maintained stable operations and recorded positive growth results.

Total revenue reached VND 1,107.2 billion, reflecting stability in production and business activities as well as adaptability to market conditions. Profit after tax reached VND 51.4 billion, up 51.2% compared to 2024, demonstrating clear efficiency in cost management, operational optimization, and overall system performance enhancement.

The Company’s General Director Presents the Executive Board’s Report at the Meeting

Governance Activities: Enhancing Transparency and Standardizing Systems

The report of the Board of Directors shows that in 2025, the Board maintained regular meetings and promptly issued important resolutions related to senior personnel, finance, investment, auditing, and internal governance.

Notably, the establishment of the Compliance Subcommittee under the Board of Directors contributed to improving the internal monitoring system, enhancing transparency, and ensuring compliance with GxP standards across all operations of the pharmaceutical enterprise.

In parallel, the direction and supervision of the Board of Management were carried out regularly, ensuring that business operations closely followed the resolutions of the General Meeting of Shareholders, while improving cost control and operational efficiency.

A Member of the Board of Directors Presents the 2025 Governance Report and the 2026 Objectives and Plans of the Board of Directors

Orientation for 2026: Sustainable Growth Based on Effective Governance

Entering 2026, Nam Ha Pharma continues to orient its development towards sustainable growth, focusing on effective governance, compliance, and enhancing competitiveness.

At the Meeting, the Presidium presented and received approval from the General Meeting of Shareholders for the 2026 business plan, which was developed based on practical operational assessments and a stable development orientation for the coming period.

Key targets include:

• Total revenue: VND 1,177 billion
• Total costs: VND 1,103 billion
• Profit after tax: expected to reach VND 59 billion, corresponding to a 15.2% increase compared to 2025 performance

On that basis, the Company continues to focus on strategic pillars including optimizing internal capabilities, standardizing quality, and enhancing governance efficiency. At the same time, it promotes digital transformation, invests in upgrading factories to international standards, and expands its portfolio of high-tech products.

In parallel, Nam Ha Pharma continues to develop key business channels including OTC, ETC, and contract manufacturing, expand international cooperation, promote research and development (R&D) activities, enhance production capacity in accordance with WHO-GMP standards, and aim for higher standards in the future.

The Chairman of the Board of Directors Submits to the Meeting the Proposal on Dismissal and Additional Election/Replacement of Members of the Board of Directors/Supervisory Board

The 2026 Annual General Meeting of Shareholders unanimously approved important contents, creating a legal foundation and strategic orientation for the Company’s new development phase.

The Meeting Votes to Approve Reports and Proposals Presented at the Meeting

At the same time, the Meeting conducted the election and consolidation of the Board of Directors and the Supervisory Board in accordance with legal regulations and the Company’s Charter, ensuring continuity, stability, and enhanced governance capacity for the next development phase.

The Presidium Congratulates Newly Elected Members of the Board of Directors and the Supervisory Board

With 66 years of establishment and development, along with an increasingly governance system, Nam Ha Pharma continues to affirm its position as one of the reputable pharmaceutical enterprises in Vietnam, remaining committed to sustainable development, aligning business growth with social responsibility and community health.